Starling Reports Q3 2026 Results and Full-Year 2026 Guidance
Starling Oncology reported Q3 2026 revenue of $169.8 million and positive Adjusted EBITDA of $3.4 million, reaffirming its 2026 revenue guidance between $650M and $660M. The positive financial performance signals continued operational momentum for the value-based oncology group.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed